Premium
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus
Author(s) -
Younis Naveed,
Williams Steve,
Soran Handrean
Publication year - 2009
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2009.01068.x
Subject(s) - aspirin , medicine , diabetes mellitus , primary prevention , myocardial infarction , stroke (engine) , disease , randomized controlled trial , clinical trial , intensive care medicine , endocrinology , mechanical engineering , engineering
The benefits of aspirin therapy in reducing the subsequent risk of myocardial infarction, stroke and death is well documented in individuals with cardiovascular disease including those with diabetes mellitus (DM). The evidence for aspirin use in primary prevention of cardiovascular events in DM is debatable and meta‐analyses do not suggest a proven benefit. Despite the lack of evidence, low‐dose aspirin therapy has been recommended by many current diabetes guidelines. This article reviews the results of two recently published large randomized clinical trials that have looked at primary prevention of cardiovascular events using aspirin in patients with DM.